Alex Gorsky is a Co-Founder of Alderline Group and a General Partner at ICONIQ Capital, investing in technology and healthcare enterprises.
He graduated in 1982 with a bachelor’s of science from the U.S. Military Academy at West Point, New York. Alex spent six years in the U.S. Army, finishing his career with the rank of captain and earning the Ranger tab and Airborne wings. He served in Europe, the United States, and Panama.
In 1996, Gorsky obtained a Master’s in Business Administration from the Wharton School of the University of Pennsylvania. After that, Gorsky spent eight years in various sales, marketing, and management roles at Janssen Pharmaceutica, a Johnson & Johnson unit based in New Jersey. After that, he joined Novartis Pharmaceuticals Corporation in 2004 as Chief Operating Officer and Head of General Medicines.
Gorsky was appointed Head of Pharma North America and Chief Executive Officer of Novartis in fall 2005. Gorsky oversaw the growth of Novartis’ cardiovascular franchise, which included products Diovan and Lotrel, and the launch of Enablex, a product for overactive bladder. He was also involved in the launch of Focalin XR for ADHD. During his tenure, he developed Novartis’ Medicare strategy and created several Novartis awards.
In 2012 Gorsky rejoined Johnson & Johnson, where he served as Chairman and CEO until January 2022. He was the seventh person who was the company’s chairman and CEO since it became a publicly traded company in 1944.
Before the appointment to CEO, Gorsky was the worldwide chairman of the medical devices and diagnostics group at Johnson & Johnson, serving in that role since September 2009. Prior to that, Gorsky served as the worldwide chairman of the surgical care group at Johnson & Johnson and as the chairman of the company’s pharmaceutical business in Europe, the Middle East and Africa.
Now retired, Alex, is a board director of Apple, IBM, and JP Morgan Chase.